nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Cisplatin—germ cell cancer	0.322	0.564	CbGbCtD
Bortezomib—PTGS1—Ifosfamide—germ cell cancer	0.0579	0.102	CbGbCtD
Bortezomib—CYP2C8—Ifosfamide—germ cell cancer	0.0334	0.0586	CbGbCtD
Bortezomib—CYP2C19—Ifosfamide—germ cell cancer	0.028	0.0492	CbGbCtD
Bortezomib—PTGS1—Etoposide—germ cell cancer	0.0277	0.0485	CbGbCtD
Bortezomib—CYP2C9—Ifosfamide—germ cell cancer	0.0233	0.0409	CbGbCtD
Bortezomib—CYP2C8—Etoposide—germ cell cancer	0.016	0.028	CbGbCtD
Bortezomib—CYP3A4—Ifosfamide—germ cell cancer	0.0135	0.0238	CbGbCtD
Bortezomib—CYP1A2—Etoposide—germ cell cancer	0.0124	0.0217	CbGbCtD
Bortezomib—CYP2C9—Cisplatin—germ cell cancer	0.0113	0.0199	CbGbCtD
Bortezomib—CYP2D6—Vinblastine—germ cell cancer	0.0113	0.0198	CbGbCtD
Bortezomib—CYP3A4—Vinblastine—germ cell cancer	0.00719	0.0126	CbGbCtD
Bortezomib—CYP3A4—Etoposide—germ cell cancer	0.00648	0.0114	CbGbCtD
Bortezomib—CYP2C9—cardial valve—germ cell cancer	0.00417	0.032	CbGeAlD
Bortezomib—PSMB2—skin epidermis—germ cell cancer	0.00257	0.0197	CbGeAlD
Bortezomib—PSMA1—embryo—germ cell cancer	0.00184	0.0142	CbGeAlD
Bortezomib—PSMD1—trigeminal ganglion—germ cell cancer	0.0016	0.0123	CbGeAlD
Bortezomib—CTSG—skin of body—germ cell cancer	0.00149	0.0114	CbGeAlD
Bortezomib—PSMB8—Vinorelbine—Vinblastine—germ cell cancer	0.00143	0.35	CbGdCrCtD
Bortezomib—PSMB8—Podofilox—Etoposide—germ cell cancer	0.00143	0.35	CbGdCrCtD
Bortezomib—PSMA1—skin of body—germ cell cancer	0.00143	0.011	CbGeAlD
Bortezomib—PSMD2—trigeminal ganglion—germ cell cancer	0.00142	0.0109	CbGeAlD
Bortezomib—PSMB8—trigeminal ganglion—germ cell cancer	0.00141	0.0108	CbGeAlD
Bortezomib—PSMD1—eye—germ cell cancer	0.00138	0.0106	CbGeAlD
Bortezomib—PSMD2—embryo—germ cell cancer	0.00137	0.0105	CbGeAlD
Bortezomib—PSMD1—retina—germ cell cancer	0.00137	0.0105	CbGeAlD
Bortezomib—PSMD1—telencephalon—germ cell cancer	0.00126	0.00966	CbGeAlD
Bortezomib—PSMA1—gonad—germ cell cancer	0.00125	0.00961	CbGeAlD
Bortezomib—PSMB5—trigeminal ganglion—germ cell cancer	0.00125	0.00957	CbGeAlD
Bortezomib—PSMA1—uterus—germ cell cancer	0.00124	0.00954	CbGeAlD
Bortezomib—PSMB8—Vincristine—Vinblastine—germ cell cancer	0.00123	0.3	CbGdCrCtD
Bortezomib—PSMD2—eye—germ cell cancer	0.00122	0.00939	CbGeAlD
Bortezomib—PSMD2—retina—germ cell cancer	0.00121	0.00931	CbGeAlD
Bortezomib—PSMD1—decidua—germ cell cancer	0.00119	0.00916	CbGeAlD
Bortezomib—CYP2C19—urine—germ cell cancer	0.00116	0.0089	CbGeAlD
Bortezomib—CTSG—adrenal gland—germ cell cancer	0.00114	0.00872	CbGeAlD
Bortezomib—PSMD2—telencephalon—germ cell cancer	0.00112	0.00856	CbGeAlD
Bortezomib—CTSG—bone marrow—germ cell cancer	0.0011	0.00844	CbGeAlD
Bortezomib—PSMA1—adrenal gland—germ cell cancer	0.00109	0.00837	CbGeAlD
Bortezomib—PSMB1—trigeminal ganglion—germ cell cancer	0.00109	0.00836	CbGeAlD
Bortezomib—PSMD2—skin of body—germ cell cancer	0.00106	0.00817	CbGeAlD
Bortezomib—PSMB2—trigeminal ganglion—germ cell cancer	0.00106	0.00816	CbGeAlD
Bortezomib—PSMD2—decidua—germ cell cancer	0.00106	0.00811	CbGeAlD
Bortezomib—PSMA1—bone marrow—germ cell cancer	0.00106	0.0081	CbGeAlD
Bortezomib—PSMB1—embryo—germ cell cancer	0.00105	0.00808	CbGeAlD
Bortezomib—PSMB8—decidua—germ cell cancer	0.00105	0.00806	CbGeAlD
Bortezomib—PSMD1—uterus—germ cell cancer	0.00104	0.00801	CbGeAlD
Bortezomib—PSMB2—embryo—germ cell cancer	0.00103	0.00788	CbGeAlD
Bortezomib—PSMD1—pituitary gland—germ cell cancer	0.00103	0.00787	CbGeAlD
Bortezomib—PSMA1—female gonad—germ cell cancer	0.00102	0.00781	CbGeAlD
Bortezomib—PSMD1—medulla oblongata—germ cell cancer	0.000989	0.00759	CbGeAlD
Bortezomib—CTSG—endocrine gland—germ cell cancer	0.000985	0.00756	CbGeAlD
Bortezomib—PSMB5—telencephalon—germ cell cancer	0.000979	0.00752	CbGeAlD
Bortezomib—CYP1A2—urine—germ cell cancer	0.000947	0.00727	CbGeAlD
Bortezomib—PSMA1—endocrine gland—germ cell cancer	0.000946	0.00726	CbGeAlD
Bortezomib—CTSG—testis—germ cell cancer	0.00094	0.00721	CbGeAlD
Bortezomib—PSMB1—eye—germ cell cancer	0.000939	0.00721	CbGeAlD
Bortezomib—PSMA1—head—germ cell cancer	0.000934	0.00717	CbGeAlD
Bortezomib—PSMD2—gonad—germ cell cancer	0.000931	0.00714	CbGeAlD
Bortezomib—PSMB5—decidua—germ cell cancer	0.000928	0.00712	CbGeAlD
Bortezomib—PSMD2—uterus—germ cell cancer	0.000925	0.0071	CbGeAlD
Bortezomib—SLC31A1—trigeminal ganglion—germ cell cancer	0.000921	0.00707	CbGeAlD
Bortezomib—PSMB2—eye—germ cell cancer	0.000916	0.00703	CbGeAlD
Bortezomib—PSMD1—adrenal gland—germ cell cancer	0.000916	0.00703	CbGeAlD
Bortezomib—PSMD2—pituitary gland—germ cell cancer	0.000908	0.00697	CbGeAlD
Bortezomib—PSMB2—retina—germ cell cancer	0.000908	0.00697	CbGeAlD
Bortezomib—PSMD1—midbrain—germ cell cancer	0.000904	0.00694	CbGeAlD
Bortezomib—PSMB8—pituitary gland—germ cell cancer	0.000903	0.00693	CbGeAlD
Bortezomib—PSMA1—testis—germ cell cancer	0.000902	0.00692	CbGeAlD
Bortezomib—CYP2C9—urine—germ cell cancer	0.000899	0.0069	CbGeAlD
Bortezomib—PSMD1—bone marrow—germ cell cancer	0.000886	0.0068	CbGeAlD
Bortezomib—PSMD1—spinal cord—germ cell cancer	0.000882	0.00677	CbGeAlD
Bortezomib—PSMD2—medulla oblongata—germ cell cancer	0.000876	0.00673	CbGeAlD
Bortezomib—PSMB1—telencephalon—germ cell cancer	0.000856	0.00657	CbGeAlD
Bortezomib—PSMD1—female gonad—germ cell cancer	0.000854	0.00655	CbGeAlD
Bortezomib—PSMB2—telencephalon—germ cell cancer	0.000835	0.00641	CbGeAlD
Bortezomib—PSMA1—cerebellum—germ cell cancer	0.000833	0.00639	CbGeAlD
Bortezomib—PSMB1—skin of body—germ cell cancer	0.000817	0.00627	CbGeAlD
Bortezomib—PSMB5—uterus—germ cell cancer	0.000812	0.00623	CbGeAlD
Bortezomib—PSMD2—adrenal gland—germ cell cancer	0.000811	0.00623	CbGeAlD
Bortezomib—PSMB1—decidua—germ cell cancer	0.000811	0.00623	CbGeAlD
Bortezomib—PSMB8—adrenal gland—germ cell cancer	0.000806	0.00619	CbGeAlD
Bortezomib—PSMD2—midbrain—germ cell cancer	0.000801	0.00615	CbGeAlD
Bortezomib—PSMB5—pituitary gland—germ cell cancer	0.000797	0.00612	CbGeAlD
Bortezomib—PSMB2—skin of body—germ cell cancer	0.000797	0.00612	CbGeAlD
Bortezomib—PSMB2—decidua—germ cell cancer	0.000792	0.00607	CbGeAlD
Bortezomib—PSMD2—bone marrow—germ cell cancer	0.000785	0.00602	CbGeAlD
Bortezomib—PSMD2—spinal cord—germ cell cancer	0.000782	0.006	CbGeAlD
Bortezomib—PSMB8—bone marrow—germ cell cancer	0.00078	0.00599	CbGeAlD
Bortezomib—PSMB5—medulla oblongata—germ cell cancer	0.000769	0.0059	CbGeAlD
Bortezomib—PSMD1—testis—germ cell cancer	0.000758	0.00581	CbGeAlD
Bortezomib—CYP1A1—skin epidermis—germ cell cancer	0.000757	0.00581	CbGeAlD
Bortezomib—PSMD2—female gonad—germ cell cancer	0.000757	0.00581	CbGeAlD
Bortezomib—PSMB8—female gonad—germ cell cancer	0.000752	0.00577	CbGeAlD
Bortezomib—PSMB1—gonad—germ cell cancer	0.000714	0.00548	CbGeAlD
Bortezomib—PSMB5—adrenal gland—germ cell cancer	0.000712	0.00547	CbGeAlD
Bortezomib—PSMB1—uterus—germ cell cancer	0.00071	0.00545	CbGeAlD
Bortezomib—PSMD2—endocrine gland—germ cell cancer	0.000704	0.0054	CbGeAlD
Bortezomib—PSMB5—midbrain—germ cell cancer	0.000703	0.0054	CbGeAlD
Bortezomib—PSMD1—cerebellum—germ cell cancer	0.0007	0.00537	CbGeAlD
Bortezomib—PSMB2—gonad—germ cell cancer	0.000697	0.00535	CbGeAlD
Bortezomib—PSMB1—pituitary gland—germ cell cancer	0.000697	0.00535	CbGeAlD
Bortezomib—PSMD2—head—germ cell cancer	0.000695	0.00533	CbGeAlD
Bortezomib—PSMB2—uterus—germ cell cancer	0.000692	0.00531	CbGeAlD
Bortezomib—PSMB5—bone marrow—germ cell cancer	0.000689	0.00529	CbGeAlD
Bortezomib—PSMB5—spinal cord—germ cell cancer	0.000686	0.00527	CbGeAlD
Bortezomib—CYP3A4—urine—germ cell cancer	0.000686	0.00526	CbGeAlD
Bortezomib—CTSG—lymph node—germ cell cancer	0.000681	0.00523	CbGeAlD
Bortezomib—PSMB2—pituitary gland—germ cell cancer	0.00068	0.00522	CbGeAlD
Bortezomib—PSMA1—brain—germ cell cancer	0.000677	0.00519	CbGeAlD
Bortezomib—CYP2D6—urine—germ cell cancer	0.000675	0.00518	CbGeAlD
Bortezomib—PSMB1—medulla oblongata—germ cell cancer	0.000673	0.00516	CbGeAlD
Bortezomib—PSMD2—testis—germ cell cancer	0.000671	0.00515	CbGeAlD
Bortezomib—PSMB8—testis—germ cell cancer	0.000667	0.00512	CbGeAlD
Bortezomib—PSMB5—female gonad—germ cell cancer	0.000664	0.0051	CbGeAlD
Bortezomib—PSMB2—medulla oblongata—germ cell cancer	0.000656	0.00504	CbGeAlD
Bortezomib—PSMA1—lymph node—germ cell cancer	0.000654	0.00502	CbGeAlD
Bortezomib—PSMB1—adrenal gland—germ cell cancer	0.000623	0.00478	CbGeAlD
Bortezomib—PSMD2—cerebellum—germ cell cancer	0.00062	0.00476	CbGeAlD
Bortezomib—PSMB1—midbrain—germ cell cancer	0.000615	0.00472	CbGeAlD
Bortezomib—PSMB2—adrenal gland—germ cell cancer	0.000607	0.00466	CbGeAlD
Bortezomib—SLC31A1—gonad—germ cell cancer	0.000604	0.00463	CbGeAlD
Bortezomib—PSMB1—bone marrow—germ cell cancer	0.000602	0.00462	CbGeAlD
Bortezomib—PSMB2—midbrain—germ cell cancer	0.0006	0.0046	CbGeAlD
Bortezomib—PSMB1—spinal cord—germ cell cancer	0.0006	0.0046	CbGeAlD
Bortezomib—PSMB5—testis—germ cell cancer	0.000589	0.00452	CbGeAlD
Bortezomib—SLC31A1—pituitary gland—germ cell cancer	0.000589	0.00452	CbGeAlD
Bortezomib—PSMB2—bone marrow—germ cell cancer	0.000588	0.00451	CbGeAlD
Bortezomib—PSMB2—spinal cord—germ cell cancer	0.000585	0.00449	CbGeAlD
Bortezomib—PSMB1—female gonad—germ cell cancer	0.000581	0.00446	CbGeAlD
Bortezomib—SLC31A1—medulla oblongata—germ cell cancer	0.000568	0.00436	CbGeAlD
Bortezomib—PSMD1—brain—germ cell cancer	0.000568	0.00436	CbGeAlD
Bortezomib—PSMB2—female gonad—germ cell cancer	0.000566	0.00435	CbGeAlD
Bortezomib—PTGS1—ganglion—germ cell cancer	0.000559	0.00429	CbGeAlD
Bortezomib—PSMD1—lymph node—germ cell cancer	0.000549	0.00421	CbGeAlD
Bortezomib—PSMB5—cerebellum—germ cell cancer	0.000544	0.00418	CbGeAlD
Bortezomib—PSMB1—endocrine gland—germ cell cancer	0.00054	0.00414	CbGeAlD
Bortezomib—PSMB1—head—germ cell cancer	0.000533	0.00409	CbGeAlD
Bortezomib—PSMB2—endocrine gland—germ cell cancer	0.000527	0.00404	CbGeAlD
Bortezomib—SLC31A1—adrenal gland—germ cell cancer	0.000526	0.00404	CbGeAlD
Bortezomib—PSMB2—head—germ cell cancer	0.00052	0.00399	CbGeAlD
Bortezomib—SLC31A1—midbrain—germ cell cancer	0.000519	0.00399	CbGeAlD
Bortezomib—PSMB1—testis—germ cell cancer	0.000515	0.00395	CbGeAlD
Bortezomib—SLC31A1—bone marrow—germ cell cancer	0.000509	0.00391	CbGeAlD
Bortezomib—SLC31A1—spinal cord—germ cell cancer	0.000507	0.00389	CbGeAlD
Bortezomib—PSMD2—brain—germ cell cancer	0.000503	0.00386	CbGeAlD
Bortezomib—PSMB2—testis—germ cell cancer	0.000502	0.00386	CbGeAlD
Bortezomib—PSMB8—brain—germ cell cancer	0.0005	0.00384	CbGeAlD
Bortezomib—SLC31A1—female gonad—germ cell cancer	0.000491	0.00376	CbGeAlD
Bortezomib—PSMD2—lymph node—germ cell cancer	0.000486	0.00373	CbGeAlD
Bortezomib—PSMB8—lymph node—germ cell cancer	0.000483	0.00371	CbGeAlD
Bortezomib—PTGS1—endothelium—germ cell cancer	0.000482	0.0037	CbGeAlD
Bortezomib—PSMB1—cerebellum—germ cell cancer	0.000476	0.00365	CbGeAlD
Bortezomib—PSMB2—cerebellum—germ cell cancer	0.000464	0.00356	CbGeAlD
Bortezomib—SLC31A1—endocrine gland—germ cell cancer	0.000456	0.0035	CbGeAlD
Bortezomib—SLC31A1—head—germ cell cancer	0.00045	0.00346	CbGeAlD
Bortezomib—PTGS1—blood vessel—germ cell cancer	0.000445	0.00341	CbGeAlD
Bortezomib—PSMB5—brain—germ cell cancer	0.000442	0.00339	CbGeAlD
Bortezomib—SLC31A1—testis—germ cell cancer	0.000435	0.00334	CbGeAlD
Bortezomib—PSMB5—lymph node—germ cell cancer	0.000427	0.00328	CbGeAlD
Bortezomib—SLC31A1—cerebellum—germ cell cancer	0.000402	0.00308	CbGeAlD
Bortezomib—PSMB1—brain—germ cell cancer	0.000386	0.00296	CbGeAlD
Bortezomib—PSMB2—brain—germ cell cancer	0.000377	0.00289	CbGeAlD
Bortezomib—PSMB1—lymph node—germ cell cancer	0.000373	0.00286	CbGeAlD
Bortezomib—PSMB2—lymph node—germ cell cancer	0.000364	0.00279	CbGeAlD
Bortezomib—SLC31A1—brain—germ cell cancer	0.000326	0.0025	CbGeAlD
Bortezomib—SLC31A1—lymph node—germ cell cancer	0.000315	0.00242	CbGeAlD
Bortezomib—CYP1A1—skin of body—germ cell cancer	0.000234	0.0018	CbGeAlD
Bortezomib—CYP2C8—pituitary gland—germ cell cancer	0.000217	0.00166	CbGeAlD
Bortezomib—PTGS1—telencephalon—germ cell cancer	0.000216	0.00166	CbGeAlD
Bortezomib—PTGS1—skin of body—germ cell cancer	0.000206	0.00158	CbGeAlD
Bortezomib—CYP1A1—uterus—germ cell cancer	0.000204	0.00156	CbGeAlD
Bortezomib—CYP2D6—brainstem—germ cell cancer	0.0002	0.00153	CbGeAlD
Bortezomib—CYP2C19—endocrine gland—germ cell cancer	0.000192	0.00148	CbGeAlD
Bortezomib—PTGS1—uterus—germ cell cancer	0.000179	0.00137	CbGeAlD
Bortezomib—CYP2D6—telencephalon—germ cell cancer	0.000177	0.00136	CbGeAlD
Bortezomib—PTGS1—pituitary gland—germ cell cancer	0.000176	0.00135	CbGeAlD
Bortezomib—CYP2C8—endocrine gland—germ cell cancer	0.000168	0.00129	CbGeAlD
Bortezomib—CYP1A1—female gonad—germ cell cancer	0.000167	0.00128	CbGeAlD
Bortezomib—CYP2C8—testis—germ cell cancer	0.00016	0.00123	CbGeAlD
Bortezomib—CYP1A2—endocrine gland—germ cell cancer	0.000157	0.00121	CbGeAlD
Bortezomib—PTGS1—adrenal gland—germ cell cancer	0.000157	0.0012	CbGeAlD
Bortezomib—CYP1A1—endocrine gland—germ cell cancer	0.000155	0.00119	CbGeAlD
Bortezomib—CYP1A1—head—germ cell cancer	0.000153	0.00117	CbGeAlD
Bortezomib—PTGS1—spinal cord—germ cell cancer	0.000151	0.00116	CbGeAlD
Bortezomib—CYP2C9—endocrine gland—germ cell cancer	0.000149	0.00114	CbGeAlD
Bortezomib—PTGS1—female gonad—germ cell cancer	0.000146	0.00112	CbGeAlD
Bortezomib—PTGS1—endocrine gland—germ cell cancer	0.000136	0.00104	CbGeAlD
Bortezomib—PTGS1—head—germ cell cancer	0.000134	0.00103	CbGeAlD
Bortezomib—PTGS1—testis—germ cell cancer	0.00013	0.000996	CbGeAlD
Bortezomib—CYP2D6—female gonad—germ cell cancer	0.00012	0.000923	CbGeAlD
Bortezomib—CYP2C8—brain—germ cell cancer	0.00012	0.000922	CbGeAlD
Bortezomib—Arthralgia—Ifosfamide—germ cell cancer	0.00012	0.000527	CcSEcCtD
Bortezomib—Chest pain—Ifosfamide—germ cell cancer	0.00012	0.000527	CcSEcCtD
Bortezomib—Renal failure acute—Methotrexate—germ cell cancer	0.00012	0.000527	CcSEcCtD
Bortezomib—Flatulence—Cisplatin—germ cell cancer	0.00012	0.000526	CcSEcCtD
Bortezomib—Anorexia—Dactinomycin—germ cell cancer	0.00012	0.000526	CcSEcCtD
Bortezomib—Eye disorder—Etoposide—germ cell cancer	0.00012	0.000525	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.000119	0.000524	CcSEcCtD
Bortezomib—Flushing—Etoposide—germ cell cancer	0.000119	0.000522	CcSEcCtD
Bortezomib—Cardiac disorder—Etoposide—germ cell cancer	0.000119	0.000522	CcSEcCtD
Bortezomib—Discomfort—Ifosfamide—germ cell cancer	0.000119	0.000521	CcSEcCtD
Bortezomib—Hypersensitivity—Vinblastine—germ cell cancer	0.000117	0.000516	CcSEcCtD
Bortezomib—Decreased appetite—Bleomycin—germ cell cancer	0.000117	0.000514	CcSEcCtD
Bortezomib—Muscle spasms—Cisplatin—germ cell cancer	0.000117	0.000513	CcSEcCtD
Bortezomib—Angiopathy—Etoposide—germ cell cancer	0.000116	0.00051	CcSEcCtD
Bortezomib—Confusional state—Ifosfamide—germ cell cancer	0.000116	0.00051	CcSEcCtD
Bortezomib—Immune system disorder—Etoposide—germ cell cancer	0.000116	0.000508	CcSEcCtD
Bortezomib—Mediastinal disorder—Etoposide—germ cell cancer	0.000115	0.000506	CcSEcCtD
Bortezomib—Pain—Bleomycin—germ cell cancer	0.000115	0.000506	CcSEcCtD
Bortezomib—Anaphylactic shock—Ifosfamide—germ cell cancer	0.000115	0.000505	CcSEcCtD
Bortezomib—Oedema—Ifosfamide—germ cell cancer	0.000115	0.000505	CcSEcCtD
Bortezomib—Chills—Etoposide—germ cell cancer	0.000115	0.000504	CcSEcCtD
Bortezomib—Vision blurred—Cisplatin—germ cell cancer	0.000115	0.000503	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000114	0.000503	CcSEcCtD
Bortezomib—Asthenia—Vinblastine—germ cell cancer	0.000114	0.000502	CcSEcCtD
Bortezomib—Infection—Ifosfamide—germ cell cancer	0.000114	0.000502	CcSEcCtD
Bortezomib—Tremor—Cisplatin—germ cell cancer	0.000114	0.0005	CcSEcCtD
Bortezomib—CYP3A4—endocrine gland—germ cell cancer	0.000114	0.000873	CbGeAlD
Bortezomib—Lethargy—Methotrexate—germ cell cancer	0.000113	0.000496	CcSEcCtD
Bortezomib—Nervous system disorder—Ifosfamide—germ cell cancer	0.000113	0.000496	CcSEcCtD
Bortezomib—Ill-defined disorder—Cisplatin—germ cell cancer	0.000113	0.000495	CcSEcCtD
Bortezomib—Thrombocytopenia—Ifosfamide—germ cell cancer	0.000113	0.000495	CcSEcCtD
Bortezomib—Anaemia—Cisplatin—germ cell cancer	0.000112	0.000494	CcSEcCtD
Bortezomib—CYP2D6—endocrine gland—germ cell cancer	0.000112	0.000859	CbGeAlD
Bortezomib—Skin disorder—Ifosfamide—germ cell cancer	0.000112	0.000491	CcSEcCtD
Bortezomib—Hyperhidrosis—Ifosfamide—germ cell cancer	0.000111	0.000489	CcSEcCtD
Bortezomib—Feeling abnormal—Bleomycin—germ cell cancer	0.000111	0.000487	CcSEcCtD
Bortezomib—CYP1A1—brain—germ cell cancer	0.000111	0.000851	CbGeAlD
Bortezomib—Osteoarthritis—Methotrexate—germ cell cancer	0.000111	0.000487	CcSEcCtD
Bortezomib—CYP2D6—head—germ cell cancer	0.00011	0.000848	CbGeAlD
Bortezomib—Anorexia—Ifosfamide—germ cell cancer	0.00011	0.000482	CcSEcCtD
Bortezomib—Malaise—Cisplatin—germ cell cancer	0.00011	0.000482	CcSEcCtD
Bortezomib—Decreased appetite—Dactinomycin—germ cell cancer	0.000109	0.00048	CcSEcCtD
Bortezomib—Diarrhoea—Vinblastine—germ cell cancer	0.000109	0.000479	CcSEcCtD
Bortezomib—Dysgeusia—Etoposide—germ cell cancer	0.000109	0.000479	CcSEcCtD
Bortezomib—Leukopenia—Cisplatin—germ cell cancer	0.000109	0.000478	CcSEcCtD
Bortezomib—Fatigue—Dactinomycin—germ cell cancer	0.000108	0.000476	CcSEcCtD
Bortezomib—Back pain—Etoposide—germ cell cancer	0.000108	0.000473	CcSEcCtD
Bortezomib—Hypotension—Ifosfamide—germ cell cancer	0.000107	0.000472	CcSEcCtD
Bortezomib—Pain—Dactinomycin—germ cell cancer	0.000107	0.000472	CcSEcCtD
Bortezomib—CYP1A1—lymph node—germ cell cancer	0.000107	0.000822	CbGeAlD
Bortezomib—Muscle spasms—Etoposide—germ cell cancer	0.000107	0.00047	CcSEcCtD
Bortezomib—Urticaria—Bleomycin—germ cell cancer	0.000107	0.00047	CcSEcCtD
Bortezomib—CYP2D6—testis—germ cell cancer	0.000107	0.000819	CbGeAlD
Bortezomib—Body temperature increased—Bleomycin—germ cell cancer	0.000106	0.000468	CcSEcCtD
Bortezomib—Irritability—Methotrexate—germ cell cancer	0.000106	0.000464	CcSEcCtD
Bortezomib—Dizziness—Vinblastine—germ cell cancer	0.000105	0.000463	CcSEcCtD
Bortezomib—Convulsion—Cisplatin—germ cell cancer	0.000105	0.000463	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000105	0.000461	CcSEcCtD
Bortezomib—Ataxia—Methotrexate—germ cell cancer	0.000104	0.000457	CcSEcCtD
Bortezomib—Myalgia—Cisplatin—germ cell cancer	0.000103	0.000455	CcSEcCtD
Bortezomib—Feeling abnormal—Dactinomycin—germ cell cancer	0.000103	0.000455	CcSEcCtD
Bortezomib—Paraesthesia—Ifosfamide—germ cell cancer	0.000103	0.000454	CcSEcCtD
Bortezomib—Ill-defined disorder—Etoposide—germ cell cancer	0.000103	0.000454	CcSEcCtD
Bortezomib—Anxiety—Cisplatin—germ cell cancer	0.000103	0.000453	CcSEcCtD
Bortezomib—Anaemia—Etoposide—germ cell cancer	0.000103	0.000452	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.000103	0.000451	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.000103	0.000451	CcSEcCtD
Bortezomib—Dyspnoea—Ifosfamide—germ cell cancer	0.000103	0.000451	CcSEcCtD
Bortezomib—Discomfort—Cisplatin—germ cell cancer	0.000102	0.000449	CcSEcCtD
Bortezomib—Vomiting—Vinblastine—germ cell cancer	0.000101	0.000445	CcSEcCtD
Bortezomib—Malaise—Etoposide—germ cell cancer	0.0001	0.000441	CcSEcCtD
Bortezomib—Breast disorder—Methotrexate—germ cell cancer	0.0001	0.00044	CcSEcCtD
Bortezomib—Vertigo—Etoposide—germ cell cancer	0.0001	0.000439	CcSEcCtD
Bortezomib—Decreased appetite—Ifosfamide—germ cell cancer	0.0001	0.000439	CcSEcCtD
Bortezomib—Headache—Vinblastine—germ cell cancer	9.98e-05	0.000439	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Methotrexate—germ cell cancer	9.97e-05	0.000438	CcSEcCtD
Bortezomib—Leukopenia—Etoposide—germ cell cancer	9.96e-05	0.000438	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	9.93e-05	0.000436	CcSEcCtD
Bortezomib—Abdominal pain—Dactinomycin—germ cell cancer	9.92e-05	0.000436	CcSEcCtD
Bortezomib—Body temperature increased—Dactinomycin—germ cell cancer	9.92e-05	0.000436	CcSEcCtD
Bortezomib—Fatigue—Ifosfamide—germ cell cancer	9.92e-05	0.000436	CcSEcCtD
Bortezomib—Anaphylactic shock—Cisplatin—germ cell cancer	9.92e-05	0.000436	CcSEcCtD
Bortezomib—Oedema—Cisplatin—germ cell cancer	9.92e-05	0.000436	CcSEcCtD
Bortezomib—Hypersensitivity—Bleomycin—germ cell cancer	9.92e-05	0.000436	CcSEcCtD
Bortezomib—CYP2D6—cerebellum—germ cell cancer	9.85e-05	0.000756	CbGeAlD
Bortezomib—Infection—Cisplatin—germ cell cancer	9.85e-05	0.000433	CcSEcCtD
Bortezomib—Pain—Ifosfamide—germ cell cancer	9.84e-05	0.000432	CcSEcCtD
Bortezomib—Constipation—Ifosfamide—germ cell cancer	9.84e-05	0.000432	CcSEcCtD
Bortezomib—Loss of consciousness—Etoposide—germ cell cancer	9.78e-05	0.00043	CcSEcCtD
Bortezomib—PTGS1—brain—germ cell cancer	9.74e-05	0.000747	CbGeAlD
Bortezomib—Nervous system disorder—Cisplatin—germ cell cancer	9.73e-05	0.000427	CcSEcCtD
Bortezomib—Cough—Etoposide—germ cell cancer	9.71e-05	0.000427	CcSEcCtD
Bortezomib—Thrombocytopenia—Cisplatin—germ cell cancer	9.71e-05	0.000427	CcSEcCtD
Bortezomib—Tachycardia—Cisplatin—germ cell cancer	9.68e-05	0.000425	CcSEcCtD
Bortezomib—Asthenia—Bleomycin—germ cell cancer	9.66e-05	0.000424	CcSEcCtD
Bortezomib—Convulsion—Etoposide—germ cell cancer	9.65e-05	0.000424	CcSEcCtD
Bortezomib—Skin disorder—Cisplatin—germ cell cancer	9.63e-05	0.000423	CcSEcCtD
Bortezomib—Hypertension—Etoposide—germ cell cancer	9.61e-05	0.000422	CcSEcCtD
Bortezomib—Hyperhidrosis—Cisplatin—germ cell cancer	9.59e-05	0.000421	CcSEcCtD
Bortezomib—Pruritus—Bleomycin—germ cell cancer	9.52e-05	0.000418	CcSEcCtD
Bortezomib—Feeling abnormal—Ifosfamide—germ cell cancer	9.48e-05	0.000417	CcSEcCtD
Bortezomib—Chest pain—Etoposide—germ cell cancer	9.48e-05	0.000416	CcSEcCtD
Bortezomib—Nausea—Vinblastine—germ cell cancer	9.47e-05	0.000416	CcSEcCtD
Bortezomib—Anorexia—Cisplatin—germ cell cancer	9.45e-05	0.000415	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	9.41e-05	0.000414	CcSEcCtD
Bortezomib—PTGS1—lymph node—germ cell cancer	9.41e-05	0.000722	CbGeAlD
Bortezomib—Gastrointestinal pain—Ifosfamide—germ cell cancer	9.41e-05	0.000413	CcSEcCtD
Bortezomib—Pancreatitis—Methotrexate—germ cell cancer	9.38e-05	0.000412	CcSEcCtD
Bortezomib—Discomfort—Etoposide—germ cell cancer	9.36e-05	0.000411	CcSEcCtD
Bortezomib—Hypotension—Cisplatin—germ cell cancer	9.27e-05	0.000407	CcSEcCtD
Bortezomib—Hypersensitivity—Dactinomycin—germ cell cancer	9.25e-05	0.000406	CcSEcCtD
Bortezomib—Abdominal discomfort—Methotrexate—germ cell cancer	9.17e-05	0.000403	CcSEcCtD
Bortezomib—Confusional state—Etoposide—germ cell cancer	9.16e-05	0.000403	CcSEcCtD
Bortezomib—Urticaria—Ifosfamide—germ cell cancer	9.14e-05	0.000402	CcSEcCtD
Bortezomib—Abdominal pain—Ifosfamide—germ cell cancer	9.09e-05	0.0004	CcSEcCtD
Bortezomib—Body temperature increased—Ifosfamide—germ cell cancer	9.09e-05	0.0004	CcSEcCtD
Bortezomib—Pancytopenia—Methotrexate—germ cell cancer	9.09e-05	0.000399	CcSEcCtD
Bortezomib—Anaphylactic shock—Etoposide—germ cell cancer	9.09e-05	0.000399	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Cisplatin—germ cell cancer	9.04e-05	0.000397	CcSEcCtD
Bortezomib—Infection—Etoposide—germ cell cancer	9.03e-05	0.000397	CcSEcCtD
Bortezomib—Asthenia—Dactinomycin—germ cell cancer	9.01e-05	0.000396	CcSEcCtD
Bortezomib—Neutropenia—Methotrexate—germ cell cancer	8.95e-05	0.000393	CcSEcCtD
Bortezomib—Paraesthesia—Cisplatin—germ cell cancer	8.9e-05	0.000391	CcSEcCtD
Bortezomib—Thrombocytopenia—Etoposide—germ cell cancer	8.9e-05	0.000391	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Methotrexate—germ cell cancer	8.89e-05	0.000391	CcSEcCtD
Bortezomib—Tachycardia—Etoposide—germ cell cancer	8.87e-05	0.00039	CcSEcCtD
Bortezomib—Dyspnoea—Cisplatin—germ cell cancer	8.84e-05	0.000389	CcSEcCtD
Bortezomib—Skin disorder—Etoposide—germ cell cancer	8.82e-05	0.000388	CcSEcCtD
Bortezomib—Erectile dysfunction—Methotrexate—germ cell cancer	8.81e-05	0.000387	CcSEcCtD
Bortezomib—Hyperhidrosis—Etoposide—germ cell cancer	8.78e-05	0.000386	CcSEcCtD
Bortezomib—Photosensitivity reaction—Methotrexate—germ cell cancer	8.73e-05	0.000384	CcSEcCtD
Bortezomib—Anorexia—Etoposide—germ cell cancer	8.66e-05	0.000381	CcSEcCtD
Bortezomib—Decreased appetite—Cisplatin—germ cell cancer	8.62e-05	0.000379	CcSEcCtD
Bortezomib—Diarrhoea—Dactinomycin—germ cell cancer	8.59e-05	0.000377	CcSEcCtD
Bortezomib—Pneumonia—Methotrexate—germ cell cancer	8.58e-05	0.000377	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Cisplatin—germ cell cancer	8.56e-05	0.000376	CcSEcCtD
Bortezomib—Vomiting—Bleomycin—germ cell cancer	8.56e-05	0.000376	CcSEcCtD
Bortezomib—Infestation NOS—Methotrexate—germ cell cancer	8.53e-05	0.000375	CcSEcCtD
Bortezomib—Infestation—Methotrexate—germ cell cancer	8.53e-05	0.000375	CcSEcCtD
Bortezomib—Hypotension—Etoposide—germ cell cancer	8.49e-05	0.000373	CcSEcCtD
Bortezomib—Rash—Bleomycin—germ cell cancer	8.49e-05	0.000373	CcSEcCtD
Bortezomib—Pain—Cisplatin—germ cell cancer	8.48e-05	0.000373	CcSEcCtD
Bortezomib—Dermatitis—Bleomycin—germ cell cancer	8.48e-05	0.000373	CcSEcCtD
Bortezomib—Hypersensitivity—Ifosfamide—germ cell cancer	8.48e-05	0.000372	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Methotrexate—germ cell cancer	8.46e-05	0.000372	CcSEcCtD
Bortezomib—Renal failure—Methotrexate—germ cell cancer	8.39e-05	0.000369	CcSEcCtD
Bortezomib—Stomatitis—Methotrexate—germ cell cancer	8.32e-05	0.000365	CcSEcCtD
Bortezomib—Conjunctivitis—Methotrexate—germ cell cancer	8.29e-05	0.000364	CcSEcCtD
Bortezomib—Asthenia—Ifosfamide—germ cell cancer	8.25e-05	0.000363	CcSEcCtD
Bortezomib—Feeling abnormal—Cisplatin—germ cell cancer	8.17e-05	0.000359	CcSEcCtD
Bortezomib—Paraesthesia—Etoposide—germ cell cancer	8.16e-05	0.000358	CcSEcCtD
Bortezomib—Pruritus—Ifosfamide—germ cell cancer	8.14e-05	0.000358	CcSEcCtD
Bortezomib—Haematuria—Methotrexate—germ cell cancer	8.14e-05	0.000357	CcSEcCtD
Bortezomib—Dyspnoea—Etoposide—germ cell cancer	8.1e-05	0.000356	CcSEcCtD
Bortezomib—Hepatobiliary disease—Methotrexate—germ cell cancer	8.07e-05	0.000355	CcSEcCtD
Bortezomib—Epistaxis—Methotrexate—germ cell cancer	8.05e-05	0.000354	CcSEcCtD
Bortezomib—CYP2D6—brain—germ cell cancer	8e-05	0.000614	CbGeAlD
Bortezomib—Nausea—Bleomycin—germ cell cancer	7.99e-05	0.000351	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—germ cell cancer	7.98e-05	0.000351	CcSEcCtD
Bortezomib—Rash—Dactinomycin—germ cell cancer	7.91e-05	0.000348	CcSEcCtD
Bortezomib—Decreased appetite—Etoposide—germ cell cancer	7.9e-05	0.000347	CcSEcCtD
Bortezomib—Diarrhoea—Ifosfamide—germ cell cancer	7.87e-05	0.000346	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Etoposide—germ cell cancer	7.84e-05	0.000345	CcSEcCtD
Bortezomib—Body temperature increased—Cisplatin—germ cell cancer	7.84e-05	0.000344	CcSEcCtD
Bortezomib—Fatigue—Etoposide—germ cell cancer	7.83e-05	0.000344	CcSEcCtD
Bortezomib—Pain—Etoposide—germ cell cancer	7.77e-05	0.000341	CcSEcCtD
Bortezomib—Constipation—Etoposide—germ cell cancer	7.77e-05	0.000341	CcSEcCtD
Bortezomib—Haemoglobin—Methotrexate—germ cell cancer	7.7e-05	0.000338	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—germ cell cancer	7.66e-05	0.000337	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—germ cell cancer	7.66e-05	0.000337	CcSEcCtD
Bortezomib—Dizziness—Ifosfamide—germ cell cancer	7.61e-05	0.000334	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—germ cell cancer	7.56e-05	0.000332	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—germ cell cancer	7.51e-05	0.00033	CcSEcCtD
Bortezomib—Feeling abnormal—Etoposide—germ cell cancer	7.49e-05	0.000329	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—germ cell cancer	7.46e-05	0.000328	CcSEcCtD
Bortezomib—Gastrointestinal pain—Etoposide—germ cell cancer	7.43e-05	0.000326	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—germ cell cancer	7.38e-05	0.000324	CcSEcCtD
Bortezomib—Vomiting—Ifosfamide—germ cell cancer	7.31e-05	0.000321	CcSEcCtD
Bortezomib—Hypersensitivity—Cisplatin—germ cell cancer	7.31e-05	0.000321	CcSEcCtD
Bortezomib—Rash—Ifosfamide—germ cell cancer	7.25e-05	0.000319	CcSEcCtD
Bortezomib—Dermatitis—Ifosfamide—germ cell cancer	7.25e-05	0.000318	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—germ cell cancer	7.24e-05	0.000318	CcSEcCtD
Bortezomib—Urticaria—Etoposide—germ cell cancer	7.22e-05	0.000317	CcSEcCtD
Bortezomib—Body temperature increased—Etoposide—germ cell cancer	7.18e-05	0.000316	CcSEcCtD
Bortezomib—Abdominal pain—Etoposide—germ cell cancer	7.18e-05	0.000316	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—germ cell cancer	7.16e-05	0.000315	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—germ cell cancer	7.14e-05	0.000314	CcSEcCtD
Bortezomib—Asthenia—Cisplatin—germ cell cancer	7.12e-05	0.000313	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—germ cell cancer	7.11e-05	0.000312	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—germ cell cancer	6.95e-05	0.000305	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—germ cell cancer	6.92e-05	0.000304	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—germ cell cancer	6.9e-05	0.000303	CcSEcCtD
Bortezomib—Chills—Methotrexate—germ cell cancer	6.87e-05	0.000302	CcSEcCtD
Bortezomib—Nausea—Ifosfamide—germ cell cancer	6.83e-05	0.0003	CcSEcCtD
Bortezomib—Diarrhoea—Cisplatin—germ cell cancer	6.79e-05	0.000298	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—germ cell cancer	6.71e-05	0.000295	CcSEcCtD
Bortezomib—Hypersensitivity—Etoposide—germ cell cancer	6.69e-05	0.000294	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—germ cell cancer	6.67e-05	0.000293	CcSEcCtD
Bortezomib—Erythema—Methotrexate—germ cell cancer	6.67e-05	0.000293	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—germ cell cancer	6.53e-05	0.000287	CcSEcCtD
Bortezomib—Asthenia—Etoposide—germ cell cancer	6.52e-05	0.000286	CcSEcCtD
Bortezomib—Back pain—Methotrexate—germ cell cancer	6.45e-05	0.000283	CcSEcCtD
Bortezomib—Pruritus—Etoposide—germ cell cancer	6.43e-05	0.000282	CcSEcCtD
Bortezomib—Vomiting—Cisplatin—germ cell cancer	6.31e-05	0.000277	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—germ cell cancer	6.28e-05	0.000276	CcSEcCtD
Bortezomib—Rash—Cisplatin—germ cell cancer	6.25e-05	0.000275	CcSEcCtD
Bortezomib—Dermatitis—Cisplatin—germ cell cancer	6.25e-05	0.000275	CcSEcCtD
Bortezomib—Diarrhoea—Etoposide—germ cell cancer	6.22e-05	0.000273	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—germ cell cancer	6.19e-05	0.000272	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—germ cell cancer	6.16e-05	0.000271	CcSEcCtD
Bortezomib—Malaise—Methotrexate—germ cell cancer	6.01e-05	0.000264	CcSEcCtD
Bortezomib—Dizziness—Etoposide—germ cell cancer	6.01e-05	0.000264	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—germ cell cancer	5.99e-05	0.000263	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—germ cell cancer	5.97e-05	0.000262	CcSEcCtD
Bortezomib—Nausea—Cisplatin—germ cell cancer	5.89e-05	0.000259	CcSEcCtD
Bortezomib—Cough—Methotrexate—germ cell cancer	5.82e-05	0.000256	CcSEcCtD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	5.78e-05	0.00085	CbGpPWpGaD
Bortezomib—Convulsion—Methotrexate—germ cell cancer	5.78e-05	0.000254	CcSEcCtD
Bortezomib—Vomiting—Etoposide—germ cell cancer	5.78e-05	0.000254	CcSEcCtD
Bortezomib—PSMD2—Signaling by Wnt—MYC—germ cell cancer	5.76e-05	0.000847	CbGpPWpGaD
Bortezomib—PSMB5—RNF mutants show enhanced WNT signaling and proliferation—MYC—germ cell cancer	5.76e-05	0.000846	CbGpPWpGaD
Bortezomib—PSMB1—RNF mutants show enhanced WNT signaling and proliferation—MYC—germ cell cancer	5.76e-05	0.000846	CbGpPWpGaD
Bortezomib—PSMB2—RNF mutants show enhanced WNT signaling and proliferation—MYC—germ cell cancer	5.76e-05	0.000846	CbGpPWpGaD
Bortezomib—Rash—Etoposide—germ cell cancer	5.73e-05	0.000252	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—germ cell cancer	5.72e-05	0.000251	CcSEcCtD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—HRAS—germ cell cancer	5.7e-05	0.000838	CbGpPWpGaD
Bortezomib—Headache—Etoposide—germ cell cancer	5.69e-05	0.00025	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—germ cell cancer	5.68e-05	0.000249	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—germ cell cancer	5.68e-05	0.000249	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—germ cell cancer	5.68e-05	0.000249	CcSEcCtD
Bortezomib—PSMB8—RNF mutants show enhanced WNT signaling and proliferation—MYC—germ cell cancer	5.67e-05	0.000834	CbGpPWpGaD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	5.64e-05	0.000248	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—germ cell cancer	5.61e-05	0.000246	CcSEcCtD
Bortezomib—PSMA1—Disease—H2AFZ—germ cell cancer	5.61e-05	0.000824	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KITLG—germ cell cancer	5.59e-05	0.000821	CbGpPWpGaD
Bortezomib—PSMD1—Disease—H2AFZ—germ cell cancer	5.58e-05	0.00082	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CRABP1—germ cell cancer	5.57e-05	0.000819	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CRABP1—germ cell cancer	5.57e-05	0.000819	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CRABP1—germ cell cancer	5.57e-05	0.000819	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KITLG—germ cell cancer	5.56e-05	0.000817	CbGpPWpGaD
Bortezomib—PSMD2—Disease—H2AFZ—germ cell cancer	5.55e-05	0.000816	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KITLG—germ cell cancer	5.53e-05	0.000813	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CRABP1—germ cell cancer	5.49e-05	0.000807	CbGpPWpGaD
Bortezomib—Confusional state—Methotrexate—germ cell cancer	5.49e-05	0.000241	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—germ cell cancer	5.44e-05	0.000239	CcSEcCtD
Bortezomib—Infection—Methotrexate—germ cell cancer	5.41e-05	0.000238	CcSEcCtD
Bortezomib—Nausea—Etoposide—germ cell cancer	5.4e-05	0.000237	CcSEcCtD
Bortezomib—PSMB2—Signaling by WNT in cancer—MYC—germ cell cancer	5.34e-05	0.000786	CbGpPWpGaD
Bortezomib—PSMB5—Signaling by WNT in cancer—MYC—germ cell cancer	5.34e-05	0.000786	CbGpPWpGaD
Bortezomib—PSMB1—Signaling by WNT in cancer—MYC—germ cell cancer	5.34e-05	0.000786	CbGpPWpGaD
Bortezomib—Nervous system disorder—Methotrexate—germ cell cancer	5.34e-05	0.000235	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—germ cell cancer	5.33e-05	0.000234	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—germ cell cancer	5.29e-05	0.000232	CcSEcCtD
Bortezomib—PSMB8—Signaling by WNT in cancer—MYC—germ cell cancer	5.27e-05	0.000775	CbGpPWpGaD
Bortezomib—Hyperhidrosis—Methotrexate—germ cell cancer	5.26e-05	0.000231	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—germ cell cancer	5.19e-05	0.000228	CcSEcCtD
Bortezomib—PSMB2—Adaptive Immune System—FGFR3—germ cell cancer	5.19e-05	0.000763	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—FGFR3—germ cell cancer	5.19e-05	0.000763	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—FGFR3—germ cell cancer	5.19e-05	0.000763	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KITLG—germ cell cancer	5.16e-05	0.000758	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—FGF4—germ cell cancer	5.15e-05	0.000757	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—FGF4—germ cell cancer	5.15e-05	0.000757	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—FGF4—germ cell cancer	5.15e-05	0.000757	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—OXT—germ cell cancer	5.15e-05	0.000757	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KITLG—germ cell cancer	5.13e-05	0.000754	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—OXT—germ cell cancer	5.13e-05	0.000753	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—FGFR3—germ cell cancer	5.11e-05	0.000752	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KITLG—germ cell cancer	5.11e-05	0.000751	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—HRAS—germ cell cancer	5.1e-05	0.00075	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—HRAS—germ cell cancer	5.1e-05	0.00075	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—HRAS—germ cell cancer	5.1e-05	0.00075	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—OXT—germ cell cancer	5.1e-05	0.00075	CbGpPWpGaD
Bortezomib—Hypotension—Methotrexate—germ cell cancer	5.09e-05	0.000223	CcSEcCtD
Bortezomib—PSMB8—Immune System—FGF4—germ cell cancer	5.08e-05	0.000747	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—HRAS—germ cell cancer	5.03e-05	0.00074	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Methotrexate—germ cell cancer	4.96e-05	0.000218	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—germ cell cancer	4.92e-05	0.000216	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—germ cell cancer	4.89e-05	0.000215	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—germ cell cancer	4.85e-05	0.000213	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—MYC—germ cell cancer	4.85e-05	0.000713	CbGpPWpGaD
Bortezomib—Dyspepsia—Methotrexate—germ cell cancer	4.79e-05	0.00021	CcSEcCtD
Bortezomib—PSMB5—Adaptive Immune System—KIT—germ cell cancer	4.76e-05	0.0007	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—KIT—germ cell cancer	4.76e-05	0.0007	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—KIT—germ cell cancer	4.76e-05	0.0007	CbGpPWpGaD
Bortezomib—PSMB2—Disease—FGF4—germ cell cancer	4.76e-05	0.000699	CbGpPWpGaD
Bortezomib—PSMB1—Disease—FGF4—germ cell cancer	4.76e-05	0.000699	CbGpPWpGaD
Bortezomib—PSMB5—Disease—FGF4—germ cell cancer	4.76e-05	0.000699	CbGpPWpGaD
Bortezomib—Decreased appetite—Methotrexate—germ cell cancer	4.73e-05	0.000208	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—germ cell cancer	4.7e-05	0.000206	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—KIT—germ cell cancer	4.69e-05	0.00069	CbGpPWpGaD
Bortezomib—Fatigue—Methotrexate—germ cell cancer	4.69e-05	0.000206	CcSEcCtD
Bortezomib—PSMB8—Disease—FGF4—germ cell cancer	4.69e-05	0.000689	CbGpPWpGaD
Bortezomib—Pain—Methotrexate—germ cell cancer	4.65e-05	0.000204	CcSEcCtD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	4.61e-05	0.000677	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—H2AFZ—germ cell cancer	4.58e-05	0.000673	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—H2AFZ—germ cell cancer	4.58e-05	0.000673	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—H2AFZ—germ cell cancer	4.58e-05	0.000673	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—H2AFZ—germ cell cancer	4.51e-05	0.000663	CbGpPWpGaD
Bortezomib—Feeling abnormal—Methotrexate—germ cell cancer	4.48e-05	0.000197	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—germ cell cancer	4.45e-05	0.000196	CcSEcCtD
Bortezomib—PSMB1—Signaling by Wnt—MYC—germ cell cancer	4.41e-05	0.000648	CbGpPWpGaD
Bortezomib—PSMB5—Signaling by Wnt—MYC—germ cell cancer	4.41e-05	0.000648	CbGpPWpGaD
Bortezomib—PSMB2—Signaling by Wnt—MYC—germ cell cancer	4.41e-05	0.000648	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—FGF4—germ cell cancer	4.4e-05	0.000646	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—FGF4—germ cell cancer	4.37e-05	0.000643	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—FGF4—germ cell cancer	4.35e-05	0.00064	CbGpPWpGaD
Bortezomib—PSMB8—Signaling by Wnt—MYC—germ cell cancer	4.34e-05	0.000639	CbGpPWpGaD
Bortezomib—Urticaria—Methotrexate—germ cell cancer	4.32e-05	0.00019	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—germ cell cancer	4.3e-05	0.000189	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—germ cell cancer	4.3e-05	0.000189	CcSEcCtD
Bortezomib—PSMB1—Disease—H2AFZ—germ cell cancer	4.25e-05	0.000625	CbGpPWpGaD
Bortezomib—PSMB2—Disease—H2AFZ—germ cell cancer	4.25e-05	0.000625	CbGpPWpGaD
Bortezomib—PSMB5—Disease—H2AFZ—germ cell cancer	4.25e-05	0.000625	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KITLG—germ cell cancer	4.23e-05	0.000622	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KITLG—germ cell cancer	4.23e-05	0.000622	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KITLG—germ cell cancer	4.23e-05	0.000622	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	4.22e-05	0.000621	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle, Mitotic—MYC—germ cell cancer	4.22e-05	0.000621	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle, Mitotic—MYC—germ cell cancer	4.2e-05	0.000618	CbGpPWpGaD
Bortezomib—PSMB8—Disease—H2AFZ—germ cell cancer	4.19e-05	0.000616	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle, Mitotic—MYC—germ cell cancer	4.18e-05	0.000615	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KITLG—germ cell cancer	4.17e-05	0.000614	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—FGFR3—germ cell cancer	4.15e-05	0.00061	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—FGFR3—germ cell cancer	4.13e-05	0.000607	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—FGFR3—germ cell cancer	4.11e-05	0.000604	CbGpPWpGaD
Bortezomib—Hypersensitivity—Methotrexate—germ cell cancer	4.01e-05	0.000176	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—H2AFZ—germ cell cancer	3.93e-05	0.000577	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KITLG—germ cell cancer	3.91e-05	0.000575	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KITLG—germ cell cancer	3.91e-05	0.000575	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KITLG—germ cell cancer	3.91e-05	0.000575	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—H2AFZ—germ cell cancer	3.91e-05	0.000574	CbGpPWpGaD
Bortezomib—Asthenia—Methotrexate—germ cell cancer	3.9e-05	0.000172	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—OXT—germ cell cancer	3.9e-05	0.000574	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—OXT—germ cell cancer	3.9e-05	0.000574	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—OXT—germ cell cancer	3.9e-05	0.000574	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—H2AFZ—germ cell cancer	3.89e-05	0.000572	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KITLG—germ cell cancer	3.85e-05	0.000566	CbGpPWpGaD
Bortezomib—Pruritus—Methotrexate—germ cell cancer	3.85e-05	0.000169	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—OXT—germ cell cancer	3.85e-05	0.000566	CbGpPWpGaD
Bortezomib—PSMA1—Disease—FGFR3—germ cell cancer	3.83e-05	0.000563	CbGpPWpGaD
Bortezomib—PSMD1—Disease—FGFR3—germ cell cancer	3.81e-05	0.000561	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KIT—germ cell cancer	3.81e-05	0.00056	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—germ cell cancer	3.81e-05	0.00056	CbGpPWpGaD
Bortezomib—PSMD2—Disease—FGFR3—germ cell cancer	3.8e-05	0.000558	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KIT—germ cell cancer	3.79e-05	0.000558	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KIT—germ cell cancer	3.77e-05	0.000555	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—MYC—germ cell cancer	3.77e-05	0.000555	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	3.77e-05	0.000554	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HRAS—germ cell cancer	3.77e-05	0.000554	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—MYC—germ cell cancer	3.76e-05	0.000552	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—MYC—germ cell cancer	3.74e-05	0.00055	CbGpPWpGaD
Bortezomib—Diarrhoea—Methotrexate—germ cell cancer	3.72e-05	0.000164	CcSEcCtD
Bortezomib—PTGS1—Metabolism—SLC2A3—germ cell cancer	3.63e-05	0.000533	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KITLG—germ cell cancer	3.61e-05	0.000531	CbGpPWpGaD
Bortezomib—Dizziness—Methotrexate—germ cell cancer	3.6e-05	0.000158	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—KITLG—germ cell cancer	3.59e-05	0.000528	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KITLG—germ cell cancer	3.58e-05	0.000526	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—SLC22A3—germ cell cancer	3.57e-05	0.000525	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AVP—germ cell cancer	3.53e-05	0.000519	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KIT—germ cell cancer	3.52e-05	0.000517	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AVP—germ cell cancer	3.51e-05	0.000516	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KIT—germ cell cancer	3.5e-05	0.000515	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AVP—germ cell cancer	3.5e-05	0.000514	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KIT—germ cell cancer	3.49e-05	0.000512	CbGpPWpGaD
Bortezomib—Vomiting—Methotrexate—germ cell cancer	3.46e-05	0.000152	CcSEcCtD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	3.44e-05	0.000505	CbGpPWpGaD
Bortezomib—Rash—Methotrexate—germ cell cancer	3.43e-05	0.000151	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—germ cell cancer	3.43e-05	0.000151	CcSEcCtD
Bortezomib—Headache—Methotrexate—germ cell cancer	3.41e-05	0.00015	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—FGF4—germ cell cancer	3.33e-05	0.00049	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FGF4—germ cell cancer	3.33e-05	0.00049	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—FGF4—germ cell cancer	3.33e-05	0.00049	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—FGF4—germ cell cancer	3.28e-05	0.000483	CbGpPWpGaD
Bortezomib—Nausea—Methotrexate—germ cell cancer	3.23e-05	0.000142	CcSEcCtD
Bortezomib—PSMB1—Cell Cycle, Mitotic—MYC—germ cell cancer	3.2e-05	0.00047	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle, Mitotic—MYC—germ cell cancer	3.2e-05	0.00047	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle, Mitotic—MYC—germ cell cancer	3.2e-05	0.00047	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle, Mitotic—MYC—germ cell cancer	3.15e-05	0.000464	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—FGFR3—germ cell cancer	3.15e-05	0.000462	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—FGFR3—germ cell cancer	3.15e-05	0.000462	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—FGFR3—germ cell cancer	3.15e-05	0.000462	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—FGFR3—germ cell cancer	3.1e-05	0.000456	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—germ cell cancer	3.1e-05	0.000456	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—germ cell cancer	3.08e-05	0.000453	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—germ cell cancer	3.07e-05	0.000451	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—H2AFZ—germ cell cancer	2.97e-05	0.000437	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—H2AFZ—germ cell cancer	2.97e-05	0.000437	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—H2AFZ—germ cell cancer	2.97e-05	0.000437	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	2.94e-05	0.000432	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—H2AFZ—germ cell cancer	2.93e-05	0.000431	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CRABP1—germ cell cancer	2.91e-05	0.000428	CbGpPWpGaD
Bortezomib—PSMB1—Disease—FGFR3—germ cell cancer	2.9e-05	0.000427	CbGpPWpGaD
Bortezomib—PSMB5—Disease—FGFR3—germ cell cancer	2.9e-05	0.000427	CbGpPWpGaD
Bortezomib—PSMB2—Disease—FGFR3—germ cell cancer	2.9e-05	0.000427	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KIT—germ cell cancer	2.89e-05	0.000425	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KIT—germ cell cancer	2.89e-05	0.000425	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KIT—germ cell cancer	2.89e-05	0.000425	CbGpPWpGaD
Bortezomib—PSMB8—Disease—FGFR3—germ cell cancer	2.86e-05	0.000421	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—MYC—germ cell cancer	2.86e-05	0.000421	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—MYC—germ cell cancer	2.86e-05	0.000421	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—MYC—germ cell cancer	2.86e-05	0.000421	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KIT—germ cell cancer	2.85e-05	0.000419	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—MYC—germ cell cancer	2.82e-05	0.000415	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KITLG—germ cell cancer	2.74e-05	0.000402	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KITLG—germ cell cancer	2.74e-05	0.000402	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KITLG—germ cell cancer	2.74e-05	0.000402	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HRAS—germ cell cancer	2.72e-05	0.000399	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HRAS—germ cell cancer	2.7e-05	0.000397	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KITLG—germ cell cancer	2.7e-05	0.000397	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HRAS—germ cell cancer	2.69e-05	0.000395	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—FGFR3—germ cell cancer	2.68e-05	0.000395	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AVP—germ cell cancer	2.67e-05	0.000393	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AVP—germ cell cancer	2.67e-05	0.000393	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AVP—germ cell cancer	2.67e-05	0.000393	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—FGFR3—germ cell cancer	2.67e-05	0.000393	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KIT—germ cell cancer	2.67e-05	0.000392	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KIT—germ cell cancer	2.67e-05	0.000392	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KIT—germ cell cancer	2.67e-05	0.000392	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—FGFR3—germ cell cancer	2.66e-05	0.000391	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AVP—germ cell cancer	2.64e-05	0.000388	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KIT—germ cell cancer	2.63e-05	0.000387	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SLC2A3—germ cell cancer	2.55e-05	0.000376	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SLC22A3—germ cell cancer	2.52e-05	0.00037	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KIT—germ cell cancer	2.46e-05	0.000362	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KIT—germ cell cancer	2.45e-05	0.000361	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KIT—germ cell cancer	2.44e-05	0.000359	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—germ cell cancer	2.35e-05	0.000345	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—germ cell cancer	2.35e-05	0.000345	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—germ cell cancer	2.35e-05	0.000345	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SLC2A3—germ cell cancer	2.34e-05	0.000344	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—germ cell cancer	2.32e-05	0.00034	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SLC22A3—germ cell cancer	2.31e-05	0.000339	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC2A3—germ cell cancer	2.09e-05	0.000307	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—MYC—germ cell cancer	2.09e-05	0.000307	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—MYC—germ cell cancer	2.08e-05	0.000305	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—MYC—germ cell cancer	2.07e-05	0.000304	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC22A3—germ cell cancer	2.06e-05	0.000303	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HRAS—germ cell cancer	2.06e-05	0.000303	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HRAS—germ cell cancer	2.06e-05	0.000303	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HRAS—germ cell cancer	2.06e-05	0.000303	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CRABP1—germ cell cancer	2.05e-05	0.000302	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—FGFR3—germ cell cancer	2.03e-05	0.000299	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FGFR3—germ cell cancer	2.03e-05	0.000299	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FGFR3—germ cell cancer	2.03e-05	0.000299	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HRAS—germ cell cancer	2.03e-05	0.000298	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—FGFR3—germ cell cancer	2.01e-05	0.000295	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MYC—germ cell cancer	1.94e-05	0.000285	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MYC—germ cell cancer	1.93e-05	0.000283	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC2A3—germ cell cancer	1.92e-05	0.000283	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MYC—germ cell cancer	1.92e-05	0.000282	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC2A3—germ cell cancer	1.91e-05	0.00028	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC22A3—germ cell cancer	1.89e-05	0.000278	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CRABP1—germ cell cancer	1.88e-05	0.000277	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC22A3—germ cell cancer	1.88e-05	0.000276	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KIT—germ cell cancer	1.87e-05	0.000275	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KIT—germ cell cancer	1.87e-05	0.000275	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KIT—germ cell cancer	1.87e-05	0.000275	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KIT—germ cell cancer	1.84e-05	0.000271	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CRABP1—germ cell cancer	1.68e-05	0.000247	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HRAS—germ cell cancer	1.65e-05	0.000242	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HRAS—germ cell cancer	1.64e-05	0.000241	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HRAS—germ cell cancer	1.63e-05	0.00024	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC2A3—germ cell cancer	1.63e-05	0.000239	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC22A3—germ cell cancer	1.6e-05	0.000236	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—MYC—germ cell cancer	1.58e-05	0.000232	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—MYC—germ cell cancer	1.58e-05	0.000232	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—MYC—germ cell cancer	1.58e-05	0.000232	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—MYC—germ cell cancer	1.56e-05	0.000229	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CRABP1—germ cell cancer	1.54e-05	0.000227	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CRABP1—germ cell cancer	1.53e-05	0.000225	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—germ cell cancer	1.52e-05	0.000224	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—germ cell cancer	1.51e-05	0.000222	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—germ cell cancer	1.51e-05	0.000221	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—germ cell cancer	1.47e-05	0.000216	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—germ cell cancer	1.47e-05	0.000216	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—germ cell cancer	1.47e-05	0.000216	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—germ cell cancer	1.45e-05	0.000213	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—germ cell cancer	1.36e-05	0.000199	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—germ cell cancer	1.35e-05	0.000198	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—germ cell cancer	1.34e-05	0.000197	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CRABP1—germ cell cancer	1.31e-05	0.000192	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A3—germ cell cancer	1.26e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—germ cell cancer	1.25e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—germ cell cancer	1.25e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—germ cell cancer	1.25e-05	0.000184	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC22A3—germ cell cancer	1.24e-05	0.000182	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—germ cell cancer	1.23e-05	0.000181	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—germ cell cancer	1.15e-05	0.000169	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—germ cell cancer	1.15e-05	0.000169	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—germ cell cancer	1.15e-05	0.000169	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—germ cell cancer	1.14e-05	0.000167	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—germ cell cancer	1.11e-05	0.000164	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—germ cell cancer	1.11e-05	0.000163	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—germ cell cancer	1.1e-05	0.000162	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—germ cell cancer	1.06e-05	0.000157	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—germ cell cancer	1.06e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—germ cell cancer	1.05e-05	0.000155	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—germ cell cancer	1.03e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—germ cell cancer	1.03e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—germ cell cancer	1.03e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—germ cell cancer	1.01e-05	0.000149	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CRABP1—germ cell cancer	1.01e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—germ cell cancer	8.44e-06	0.000124	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—germ cell cancer	8.44e-06	0.000124	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—germ cell cancer	8.44e-06	0.000124	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—germ cell cancer	8.32e-06	0.000122	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—germ cell cancer	8.07e-06	0.000119	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—germ cell cancer	8.07e-06	0.000119	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—germ cell cancer	8.07e-06	0.000119	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—germ cell cancer	7.96e-06	0.000117	CbGpPWpGaD
